Approaches that can elicit expression of full-length utrophin, such as small drug treatment,18 in dystrophin-deficient hearts may have a clinically meaningful impact on the cardiomyopathy of DMD patients. This evidence concerns the gene UTRN and Duchenne muscular dystrophy.